Stock Analiz

Estrella Immunopharma, Inc. ESLA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.51Market cap $22M
Open the interactive analysis →

Estrella Immunopharma, Inc. (ESLA) is a healthcare company listed in the US with a market value of about $22M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -135%.

About Estrella Immunopharma

Estrella Immunopharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 5 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-42.0%
Shareholder yield0.1%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-135.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal year20252024202320222021
Revenue—————
Net income-$13M-$7M-$11M-$996104-$247718
Free cash flow-$2M—-$1M——
EPS (diluted)$-0.35$-0.27$-36.35—$-1.52
Net margin—————
ROIC—-135.1%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Estrella Immunopharma pay a dividend?

Not currently.

Is Estrella Immunopharma a good stock to buy?

We do not give buy or sell advice. Estrella Immunopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.